Shots: The designation is based on the ongoing P-III DIALIZE-Outcomes trial to evaluate the effect of Lokelma on arrhythmia-related CV outcomes in patients with chronic hemodialysis with recurrent HK at […]readmore
Tags : Hyperkalaemia
Regulatory
AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) Receives NMPA’s Approval for Patients
Shots: The approval is based on four trials assessing Lokelma vs PBO in patients with hyperkalemia treated for up to 12 months The study resulted in a median time of […]readmore
Shots: The P-IIIb DIALIZE study results involve assessing of Lokelma vs PBO in n 196 patients on hemodialysis with hyperkalemia in ESRD The P-IIIb DIALIZE study resulted in maintaining normal […]readmore
Shots: The global P-III HARMONIZE involves assessing of Lokelma (5/10mg) vs PBO in 267 patients with hyperkalaemia in Japan, Korea, Taiwan and Russia across 47 locations P-III HARMONIZE Results: @48 […]readmore
Shots: The approval is based on five studies assessing Lokelma vs PBO in patients with hyperkalaemia The study resulted in onset of action was at 1.0 hour and the median […]readmore